Pancreatic Ductal AdenocarcinomaNCT05692596
The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
An observational study of Pancreatic Ductal Adenocarcinoma and Pancreatic Cyst, run by H. Lee Moffitt Cancer Center and Research Institute at 1 site in United States.
Trial summary
The long-term goal of our PIC is to develop effective strategies that can be applied clinically at the point-of-care to prevent, intercept, or detect PDAC at an early stage, thereby reducing PDAC burden and saving lives. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Pancreatic Ductal Adenocarcinoma, Pancreatic Cyst, Chronic Pancreatitis
- What is being tested?
- Data collection
- How many people
- 317 participants
- Where
- 1 siteUnited States
- Study dates
- 6 Oct 2022to Jul 2027
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients presenting at the Moffitt GI clinic
Who may be able to join
- 18 years of age or older
- Moffitt Cancer Center patients presenting with a pancreatic cyst, and/or inherited syndrome that predisposes them to pancreatic ductal adenocarcinoma (PDAC)
- Moffitt Cancer Center patients undergoing evaluation for localized/early stage PDAC.
- Moffitt Cancer Center patients with a combination of PDAC risk factors such as a history of chronic or new-onset diabetes, pancreatitis, obesity, tobacco exposure, toxin exposure and/or heavy alcohol consumption.
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country.
About this study
The long-term goal of our PIC is to develop effective strategies that can be applied clinically at the point-of-care to prevent, intercept, or detect PDAC at an early stage, thereby reducing PDAC burden and saving lives.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Pancreatic Cyst, Chronic Pancreatitis, Fatty Pancreas, Genetic Pancreatic Cancer, Genetic Pancreatitis
- Being tested
- Data collection
- Keywords
- pancreas, database
- Medical subject headings
- Pancreatic Cyst, Pancreatitis, Chronic, Colorectal Neoplasms, Hereditary Nonpolyposis, Dysplastic Nevus Syndrome, Peutz-Jeghers Syndrome, Ataxia Telangiectasia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Data collectionOther
Investigators will compile data typically collected clinically. This data will include demographics, cancer screening procedures, cancer diagnosis and staging, chemotherapy, immunotherapy, radiation therapy, surgery, comorbidities, medication use, lifestyle and other cancer risk factors, quality of life, vital status, and molecular data generated from specimens collected clinically.
| Study group | Role | What they receive |
|---|---|---|
| All participants | Participants include patients scheduled to see the clinical team in the Pancreas Interception Center (PIC) which will be housed in the Moffitt GI Clinic. Receives: Other: Data collection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Database creation
A centralized, real-time, queryable and secure database will be developed that will integrate data on Moffitt patients diagnosed with pancreatic ductal adenocarcinoma (PDAC), pancreatic cystic lesions (benign, pre-cancerous and malignant), or an inherited PDAC susceptibility.
Measured: 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jan 2023
- Study start6 Oct 2022
- Primary completionJul 2027 (estimated)
- Study completionJul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pancreatic Ductal AdenocarcinomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 317 participants (estimated)
Sponsor and investigators
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Shaffer Mok, MD, MBS, Principal investigator, Moffitt Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05692596
- Sponsor's protocol ID
- MCC-22156
- Status last verified
- Sep 2026
- First submitted
- 11 Jan 2023
- Last updated
- 15 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided